[go: up one dir, main page]

AR055398A1 - PHARMACEUTICAL COMPOSITION OF SOLID DISPERSION OF PRANLUKAST WITH BETTER RATE OF INITIAL DISSOLUTION AND METHOD TO PREPARE THE COMPOSITION - Google Patents

PHARMACEUTICAL COMPOSITION OF SOLID DISPERSION OF PRANLUKAST WITH BETTER RATE OF INITIAL DISSOLUTION AND METHOD TO PREPARE THE COMPOSITION

Info

Publication number
AR055398A1
AR055398A1 ARP060103719A ARP060103719A AR055398A1 AR 055398 A1 AR055398 A1 AR 055398A1 AR P060103719 A ARP060103719 A AR P060103719A AR P060103719 A ARP060103719 A AR P060103719A AR 055398 A1 AR055398 A1 AR 055398A1
Authority
AR
Argentina
Prior art keywords
pranlukast
solid dispersion
pharmaceutical composition
solid
initial dissolution
Prior art date
Application number
ARP060103719A
Other languages
Spanish (es)
Inventor
Joon Gyo Oh
Yong Ho Oh
Ho Chu Shin
Jisun Jung
Key An Um
Dong-Sun Min
Woong Sik Kim
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37771823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055398(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of AR055398A1 publication Critical patent/AR055398A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composicion farmacéutica de una dispersion solida de pranlukast con una mejor tasa de disolucion inicial y método para su preparacion. Más específicamente, se describe una composicion farmacéutica de una dispersion solida de pranlukast preparada mezclando una dispersion solida de pranlukast con un agente anticoagulante con un rango determinado de HLB a una temperatura elevada, que puede ser procesada como gránulos y encapsulada, posibilitando un mejoramiento de la tasa inicial de disolucion del pranlukast. Se soluciona el grave problema de la adherencia de las dispersiones solidas de pranlukast a las paredes de la cápsula y se mejora la biodisponibilidad al presentar valores de Cmax y AUC más elevados comparados, en base a la misma dosis de administracion, con las composiciones farmacéuticas comerciales de pranlukast formuladas con los métodos convencionales; y método de preparacion. Reivindicacion 1: Una composicion farmacéutica de dispersion solida de pranlukast caracterizada porque comprende 100 partes en peso de dispersion solida de pranlukast y entre 0,1 y 10 partes en peso de agente de anticoagulacion, el cual está en estado solido o semi-solido a temperatura ambiente y tiene 10-40 de HLB.Pharmaceutical composition of a solid dispersion of pranlukast with a better initial dissolution rate and method for its preparation. More specifically, a pharmaceutical composition of a solid dispersion of pranlukast prepared by mixing a solid dispersion of pranlukast with an anticoagulant agent with a determined range of HLB at an elevated temperature, which can be processed as granules and encapsulated, enabling an improvement of the pharmaceutical composition is described. initial dissolution rate of pranlukast. The serious problem of the adhesion of solid dispersions of pranlukast to the capsule walls is solved and the bioavailability is improved by presenting higher Cmax and AUC values compared, based on the same administration dose, with the commercial pharmaceutical compositions of pranlukast formulated with conventional methods; and method of preparation. Claim 1: A pharmaceutical composition of solid dispersion of pranlukast characterized in that it comprises 100 parts by weight of solid dispersion of pranlukast and between 0.1 and 10 parts by weight of anticoagulation agent, which is in solid or semi-solid state at temperature environment and has 10-40 of HLB.

ARP060103719A 2005-08-26 2006-08-25 PHARMACEUTICAL COMPOSITION OF SOLID DISPERSION OF PRANLUKAST WITH BETTER RATE OF INITIAL DISSOLUTION AND METHOD TO PREPARE THE COMPOSITION AR055398A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020050078535A KR101233235B1 (en) 2005-08-26 2005-08-26 Pharmaceutical composition of pranlukast solid-dispersion with improved early dissolution rate and the method of preparing the composition

Publications (1)

Publication Number Publication Date
AR055398A1 true AR055398A1 (en) 2007-08-22

Family

ID=37771823

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103719A AR055398A1 (en) 2005-08-26 2006-08-25 PHARMACEUTICAL COMPOSITION OF SOLID DISPERSION OF PRANLUKAST WITH BETTER RATE OF INITIAL DISSOLUTION AND METHOD TO PREPARE THE COMPOSITION

Country Status (5)

Country Link
JP (1) JP5297194B2 (en)
KR (1) KR101233235B1 (en)
CN (1) CN101282716B (en)
AR (1) AR055398A1 (en)
WO (1) WO2007024123A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100981751B1 (en) * 2005-10-28 2010-09-10 주식회사유한양행 Granules containing Franlukast and preparation method thereof
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
BR112022023307A2 (en) 2020-05-18 2022-12-20 Orexo Ab PHARMACEUTICAL COMPOSITION FOR DELIVERY OF DRUGS
CA3238850A1 (en) 2021-11-25 2023-06-01 Jonas Savmarker Pharmaceutical composition comprising adrenaline
WO2025018777A1 (en) * 2023-07-18 2025-01-23 삼아제약 주식회사 Method for preparing pharmaceutical composition containing pranlukast and pharmaceutical composition prepared thereby

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019239A1 (en) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
WO1996041628A1 (en) * 1995-06-12 1996-12-27 Ono Pharmaceutical Co., Ltd. Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast
JP2958863B2 (en) * 1995-06-12 1999-10-06 小野薬品工業株式会社 Granulated product containing pranlukast, method for producing the same, and method for improving adhesion and cohesion of pranlukast
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AUPQ583600A0 (en) * 2000-02-24 2000-03-16 Cds Worldwide Pty Ltd Vehicle parking system
KR100381834B1 (en) * 2000-05-20 2003-04-26 이상득 Solid dispersion system of pranlukast with improved dissolution, and the method thereof
WO2004073692A1 (en) * 2003-02-18 2004-09-02 Yamashita, Shinji Hard capsule of hardly water-soluble drug
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
JP4544856B2 (en) * 2003-12-25 2010-09-15 日医工株式会社 Formulation containing pranlukast hydrate
KR101086254B1 (en) * 2004-11-04 2011-11-24 에스케이케미칼주식회사 Franlukast solid dispersion composition with improved bioavailability and method for preparing the solid dispersion

Also Published As

Publication number Publication date
CN101282716B (en) 2012-05-23
JP2009506027A (en) 2009-02-12
JP5297194B2 (en) 2013-09-25
KR101233235B1 (en) 2013-02-15
CN101282716A (en) 2008-10-08
KR20070024047A (en) 2007-03-02
WO2007024123A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
AR055398A1 (en) PHARMACEUTICAL COMPOSITION OF SOLID DISPERSION OF PRANLUKAST WITH BETTER RATE OF INITIAL DISSOLUTION AND METHOD TO PREPARE THE COMPOSITION
BRPI0615292A8 (en) compositions and methods for preparing poorly soluble water drugs with increased stability
CR8529A (en) NEW CRYSTAL FORM V OF AGOMELATINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
TR200801336T1 (en) Compositions and methods for the preparation of drugs with increased stability to poor water solubility.
AR110986A2 (en) ECTEINASCIDINE COMPOSITIONS, LIOFILIZED FORMULATIONS, METHOD OF PREPARATION AND USE
AR110270A1 (en) PREPARATION OF SOLID CYCLODEXTRINE COMPLEXES FOR THE ADMINISTRATION OF PHARMACEUTICAL ACTIVE INGREDIENTS
NZ706991A (en) A fast dissolving pharmaceutical composition
PE20060003A1 (en) POLYMERIC PHARMACEUTICAL FORMULATION FOR INJECTION MOLDING
NO20075136L (en) New liposome preparations
CR9292A (en) COMPRESSED WITH IMPROVED DISPERSION OF PHARMACOLOGICAL SUBSTANCE
NO20070871L (en) Multi Particle Formulation
AR054485A1 (en) ARIL-ALQUILAMINAS AND HETEROARIL-ALQUILAMINAS AS INHIBITORS OF PROTEIN QUINASA A AND B, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OR PROFILAXITY OF ENFORCEMENT
PE20080765A1 (en) PHARMACEUTICAL DOSAGE FORMS
UY31406A1 (en) "SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA BASED COMPOUND".
PE20091778A1 (en) HIGH DENSITY COMPOSITIONS CONTAINING POSACONAZOLE AND FORMULATIONS THAT INCLUDE IT
AR078159A1 (en) COMPOSITION CONTAINING PALMITOIL-ETANOLAMIDE ULTRA-MICRONIZED. METHOD. COMPOUND POLYMORPHIC FORM.
MX2017010220A (en) FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE.
AR056471A1 (en) BAZEDOXIFEN ACETATE FORMULATIONS
AR080736A1 (en) PHARMACEUTICAL COMPOSITION OF RAPID DISSOLUTION, USEFULLY DIVERSE, AND PROCESS TO PREPARE IT
PE20180522A1 (en) ORODISPERSABLE DOSING UNIT CONTAINING A STETROL COMPONENT
ATE470443T1 (en) INDOL-1-YL ACID DERIVATIVES
MX2022002548A (en) Stable medicinal cannabidiol compositions.
JP2017514924A5 (en)
AR102779A1 (en) PHARMACEUTICAL COMPOSITION, ITS PREPARATION AND ITS USES
NO20085414L (en) Pharmaceutical preparations for sustained release of phenylephrine

Legal Events

Date Code Title Description
FB Suspension of granting procedure